155 related articles for article (PubMed ID: 2162251)
1. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.
Lau DH; Ross KL; Sikic BI
Cancer Res; 1990 Jul; 50(13):4056-60. PubMed ID: 2162251
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
3. Effects of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukemia cells in vitro.
Wassermann K; Zwelling LA; Mullins TD; Silberman LE; Andersson BS; Bakic M; Acton EM; Newman RA
Cancer Res; 1986 Aug; 46(8):4041-6. PubMed ID: 3731072
[TBL] [Abstract][Full Text] [Related]
4. Activity of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin in sensitive and resistant L5178Y lymphoblasts in vitro.
Begleiter A; Leith MK; Johnston JB
Cancer Res; 1994 Jan; 54(2):482-6. PubMed ID: 8275485
[TBL] [Abstract][Full Text] [Related]
5. DNA damage in cyclophosphamide-resistant tumor cells: the role of glutathione.
Richardson ME; Siemann DW
Cancer Res; 1995 Apr; 55(8):1691-5. PubMed ID: 7712476
[TBL] [Abstract][Full Text] [Related]
6. Comparison of DNA interstrand cross-linking and strand breakage by 1,3-bis(2-chloroethyl)-1-nitrosourea in polyamine-depleted and control human adenocarcinoma cells.
Seidenfeld J; Barnes D; Block AL; Erickson LC
Cancer Res; 1987 Sep; 47(17):4538-43. PubMed ID: 3113720
[TBL] [Abstract][Full Text] [Related]
7. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
8. Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin.
Lau DH; Durán GE; Sikic BI
J Natl Cancer Inst; 1992 Oct; 84(20):1587-92. PubMed ID: 1404452
[TBL] [Abstract][Full Text] [Related]
9. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
10. DNA breakage, cytotoxicity, drug accumulation and retention in two human ovarian tumor cell lines AZ224 and AZ364 treated with adriamycin, modulated by verapamil.
Delvaeye M; Verovski V; De Neve W; Storme G
Anticancer Res; 1993; 13(5A):1533-8. PubMed ID: 8239532
[TBL] [Abstract][Full Text] [Related]
11. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
12. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues.
Duran GE; Lau DH; Lewis AD; Kühl JS; Bämmler TK; Sikic BI
Cancer Chemother Pharmacol; 1996; 38(3):210-6. PubMed ID: 8646794
[TBL] [Abstract][Full Text] [Related]
13. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.
Bellamy WT; Dorr RT; Dalton WS; Alberts DS
Cancer Res; 1988 Nov; 48(22):6360-4. PubMed ID: 3180055
[TBL] [Abstract][Full Text] [Related]
14. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
15. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
[TBL] [Abstract][Full Text] [Related]
16. DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells.
Scudder SA; Brown JM; Sikic BI
J Natl Cancer Inst; 1988 Oct; 80(16):1294-8. PubMed ID: 3172256
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
Farrell N; Povirk LF; Dange Y; DeMasters G; Gupta MS; Kohlhagen G; Khan QA; Pommier Y; Gewirtz DA
Biochem Pharmacol; 2004 Sep; 68(5):857-66. PubMed ID: 15294448
[TBL] [Abstract][Full Text] [Related]
18. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
19. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Robson CN; Hoban PR; Harris AL; Hickson ID
Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
